Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathways

Molecular Carcinogenesis

Volumn 40, Issue 3, 2004, Pages 160-170

  Qin, Chunhua ^a,b   Samudio, Ismael ^b   Ngwenya, Sharon ^a   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Estrogen; Nongenomic; Ornithine decarboxylase; Transactivation

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTRADIOL; ESTROGEN; GENE PRODUCT; LUCIFERASE; ORNITHINE DECARBOXYLASE; PROTEIN LSF; PROTEIN NFYA; SQ 22356; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CELL STRAIN MCF 7; CHIMERA; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DNA FOOTPRINTING; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME MECHANISM; ESTROGEN ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE ACTIVITY; GENE CONSTRUCT; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MOTIF; REPORTER GENE; SEQUENCE ANALYSIS; TRANSACTIVATION; UPREGULATION;

BREAST NEOPLASMS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA FOOTPRINTING; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LUCIFERASES; MUTATION; ORNITHINE DECARBOXYLASE; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS); MINK CELL FOCUS-FORMING VIRUS;

EID: 3142714386     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20030     Document Type: Article

References (77)

1. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase: Structure, function, and translational regulation. Biochem Soc Trans 1994;22:846-852.
2. Heby O, Holm I, Persson L. Polyamine-mediated control of ornithine decarboxylase and S-adenosylmethionine decarboxylase expression in mammalian cells. Biochem Soc Trans 1990;18:1084-1087.
3. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986;234:249-262.
4. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749-790.
5. Abrahamsen MS, Morris DR. Regulation of expression of the ornithine decarboxylase gene by intracellular signal transduction pathways. In: Campisi J, Cunningham DD, Inouye M, Rily M, editors. Perspectives on cellular regulation: From bacteria to cancer: Essays in honor of Arthur Pardee. New York: Wiley-Liss, Inc.; 1991. pp 107-119.
6. Persson L, Wallstrom EL, Nasizadeh S, et al. Regulation of mammalian ornithine decarboxylase. Biochem Soc Trans 1998;26:575-579.
7. O'Brien TG. The induction of ornithine decarboxylase as an early, possibly obligatory, event in mouse skin carcinogenesis. Cancer Res 1976;36:2644-2653.
8. Moshier JA, Dosescu J, Skunca M, Luk GD. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 1993;53:2618-2622.
9. Clifford A, Morgan D, Yuspa SH, Soler AP, Gilmour S. Role of ornithine decarboxylase in epidermal tumorigenesis. Cancer Res 1995;55:1680-1686.
10. Gilmour SK, Aglow E, O'Brien TG. Heterogeneity of ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin and in epidermal tumors. Carcinogenesis 1986;7:943-947.
11. Koza RA, Megosh LC, Palmieri M, O'Brien TG. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas. Carcinogenesis 1991;12:1619-1625.
12. Gilmour SK, Verma AK, Madara T, O'Brien TG. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. Cancer Res 1987;47:1221-1225.
13. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992;360:355-358.
14. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994;54:2313-2316.
15. Smith MK, Goral MA, Wright JH, et al. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 1997;57:2104-2108.
16. Bartholeyns J. Treatment of metastatic Lewis lung carcinoma with DL-α-difluoromethylornithine. Eur J Cancer Clin Oncol 1983;19:567-572.
17. Ashida Y, Kido J, Kinoshita F, et al. Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Cancer Res 1992;52:5313-5316.
18. Sunkara PS, Rosenberger AL. Antimetastatic activity of DL-α-difluoromethylornithine: An inhibitor of polyamine biosynthesis, in mice. Cancer Res 1987;47:933-935.
19. O'Brien TG, Simsiman RC, Boutwell RK. Induction of the polyamine-biosynthetic enzymes in mouse epidermis by tumor-promoting agents. Cancer Res 1975;35:1662-1670.
20. Kennard MD, Kang DC, Montgomery RL, Butler AP. Expression of epidermal ornithine decarboxylase and nuclear proto-oncogenes in phorbol ester tumor promotion-sensitive and -resistant mice. Mol Carcinog 1995;12:14-22.
21. Elitsur Y, Moshier JA, Murthy R, Barbish A, Luk GD. Polyamine levels, ornithine decarboxylase (ODC) activity, and ODC-mRNA expression in normal and cancerous human colonocytes. Life Sci 1992;50:1417-1424.
22. Takami H, Koudaira H, Kodaira S. Relationship of ornithine decarboxylase activity and human colon tumorigenesis. Jpn J Clin Oncol 1994;24:141-143.
23. Kingsnorth AN. Ornithine decarboxylase as a marker for colorectal adenomas. Br J Surg 1987;74:1066.
24. Mimori K, Mori M, Shiraishi T, et al. Expression of ornithine decarboxylase mRNA and c-myc mRNA in breast tumours. Int J Oncol 1998;12:597-601.
25. Canizares F, Salinas J, de las H, et al. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: Correlation with clinicopathologic parameters. Clin Cancer Res 1999;5:2035-2041.
26. Mohan RR, Challa A, Gupta S, et al. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999;5:143-147.
27. Glikman P, Vegh I, Pollina MA, Mosto AH, Levy CM. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 1987;60:2237-2243.
28. Bachrach U, Shayovitz A, Marom Y, Ramu A, Ramu N. Ornithine decarboxylase: A predictor for tumor chemosensitivity. Cell Mol Biol 1994;40:957-964.
29. Zhao B, Butler AP. Core promoter involvement in the induction of rat ornithine decarboxylase by phorbol esters. Mol Carcinog 2001;32:92-99.
30. Zhao B, Kumar AP, Butler AP. A negative regulatory element within the proximal promoter region of the rat ornithine decarboxylase gene. Mol Carcinog 2000;29:212-218.
31. Kim YJ, Pan H, Verma AK. Non-AP-1 tumor promoter 12-O- tetradecanoylphorbol-13-acetate-responsive sequences in the human ornithine decarboxylase gene. Mol Carcinog 1994;10:169-179.
32. Reddig PJ, Kim YJ, Verma AK. Localization of the 12-O- tetradecanoylphorbol-13-acetate response of the human ornithine decarboxylase promoter to the TATA box. Mol Carcinog 1996;17:92-104.
33. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993;90:7804-7808.
34. Walhout AJ, Gubbels JM, Bernards R, van d V, Timmers HT. c-myc/Max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (ODC) gene. Nucleic Acids Res 1997;25:1493-1501.
35. Iyengar RV, Pawlik CA, Krull EJ, et al. Use of a modified ornithine decarboxylase promoter to achieve efficient c-myc-or N-myc-regulated protein expression. Cancer Res 2001;61:3045-3052.
36. Li RS, Abrahamsen MS, Johnson RR, Morris DR. Complex interactions at a GC-rich domain regulate cell type-dependent activity of the ornithine decarboxylase promoter. J Biol Chem 1994;269:7941-7949.
37. Law GL, Itoh H, Law DJ, Mize GJ, Merchant JL, Morris DR. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J Biol Chem 1998;273:19955-19964.
38. Kumar AP, Mar PK, Zhao B, Montgomery RL, Kang DC, Butler AP. Regulation of rat ornithine decarboxylase promoter activity by binding of transcription factor Sp1. J Biol Chem 1995;270:4341-4348.
39. Kumar AP, Butler AP. Transcription factor Sp3 antagonizes activation of the ornithine decarboxylase promoter by Sp1. Nucleic Acids Res 1997;25:2012-2019.
40. Kumar AP, Butler AP. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999;137:159-165.
41. al-Asadi R, Yi EC, Merchant JL. Sp1 affinity for GC-rich elements correlates with ornithine decarboxylase promoter activity. Biochem Biophys Res Commun 1995;214:324-330.
42. Abrahamsen MS, Li RS, Dietrich-Goetz W, Morris DR. Multiple DNA elements responsible for transcriptional regulation of the ornithine decarboxylase gene by protein kinase A. J Biol Chem 1992;267:18866-18873.
43. Cohen S, O'Malley BW, Stastny M. Estrogenic induction of ornithine decarboxylase in vivo and in vitro. Science 1970;170:336-338.
44. Kaye AM, Icekson I, Lindner HR. Stimulation by estrogens of ornithine and S-adenosylmethionine decarboxylases in the immature rat uterus. Biochim Biophys Acta 1971;252:150-159.
45. Russell DH, Taylor RL. Polyamine synthesis and accumulation in the castrated rat uterus after estradiol-17-β stimulation. Endocrinology 1971;88:1397-1403.
46. Thomas T, Faaland CA, Adhikarakunnathu S, Thomas TJ. Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 1996;39:293-306.
47. Thomas T, Thomas TJ. Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: Therapeutic implications. Breast Cancer Res Treat 1994;29:189-201.
48. Rowlands JC, Casida JE. NADH: Ubiquinone oxidoreductase inhibitors block induction of ornithine decarboxylase activity in MCF-7 human breast cancer cells. Pharmacol Toxicol 1998;83:214-219.
49. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor γ (PPARγ) agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 2003;63:958-964.
50. Kladde MP, Simpson RT. Chromatin structure mapping in vivo using methyltransferases. Methods Enzymol 1996;274:214-233.
51. Kladde MP, Xu M, Simpson RT. Direct study of DNA-protein interactions in repressed and active chromatin in living cells. EMBO J 1996;15:6290-6300.
52. Savouret JF, Bailly A, Misrahi M, et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J 1991;10:1875-1883.
53. Cavailles V, Augereau P, Rochefort H. Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription. Proc Natl Acad Sci USA 1993;90:203-207.
54. Cavailles V, Garcia M, Rochefort H. Regulation of cathepsin D and pS2 gene expression by growth factors in MCF-7 human breast cancer cells. Mol Endocrinol 1989;3:552-558.
55. Zacharewski TR, Bondy KL, McDonell P, Wu ZF. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced pS2 expression. Cancer Res 1994;54:2707-2713.
56. Weisz A, Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 1990;18:5097-5106.
57. Gillesby B, Santostefano M, Porter W, Wu ZF, Safe S, Zacharewski T, Identification of a motif within the 5′-regulatory region on pS2 which is responsible for Ap1 binding and TCDD-mediated suppression. Biochemistry 1997;36:6080-6089.
58. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-456.
59. Ngwenya S, Safe S. Cell context-dependent differences in the induction of E2F-1 gene expression by 17β-estradiol in MCF-7 and ZR-75 cells. Endocrinology 2003;144:1675-1685.
60. Sathya G, Li W, Klinge CM, Anolik JH, Hilf R, Bambara RA. Effects of multiple estrogen responsive elements, their spacing and location on estrogen response of reporter genes. Mol Endocrinol 1997;11:1994-2003.
61. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994;269:15912-15917.
62. Safe S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231-252.
63. Wright PS, Cooper JR, Cross-Doersen DE, et al. Regulation of ornithine decarboxylase mRNA levels in human breast cancer cells: Pattern of expression and involvement of core enhancer promoter element. Cell Growth Differ 1995;6:1097-1102.
64. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002;67:471-475.
65. Watson CS, Campbell CH, Gametchu B. The dynamic and elusive membrane estrogen receptor-α. Steroids 2002;67:429-437.
66. Kelly MJ, Wagner EJ. Estrogen modulation of G-protein-coupled receptors. Trends Endocrinol Metab 1999;10:369-374.
67. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 1994;91:8517-8521.
68. Aronica SM, Katzenellenbogen BS. Progesterone receptor regulation in uterine cells: Stimulation by estrogen, cyclic adenosine 3′,5′- monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 1991;128:2045-2052.
69. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993;7:743-752.
70. El-Tanani MK, Green CD. Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol 1997;11:928-937.
71. Castro-Rivera E, Samudio I, Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 2001;276:30853-30861.
72. Zhong ZD, Hammani K, Bae WS, DeClerck YA. NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J Biol Chem 2000;275:18602-18610.
73. Volker JL, Rameh LE, Zhu Q, DeCaprio J, Hansen U. Mitogenic stimulation of resting T cells causes rapid phosphorylation of the transcription factor LSF and increased DNA-binding activity. Genes Dev 1997;11:1435-1446.
74. Wang W, Dong L, Saville B, Safe S. Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 1999;13:1373-1387.
75. Li-Weber M, Davydov IV, Krafft H, Krammer PH. The role of NF-Y and IRF-2 in the regulation of human IL-4 gene expression. J Immunol 1994;153:4122-4133.
76. Klein-Hessling S, Schneider G, Heinfling A, Chuvpilo S, Serfling E. HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells. Proc Natl Acad Sci USA 1996;93:15311-15316.
77. Takemoto N, Koyano-Nakagawa N, Arai N, Arai K, Yokota T. Four P-like elements are required for optimal transcription of the mouse IL-4 gene: Involvement of a distinct set of nuclear factor of activated T cells and activator protein-1 family proteins. Int Immunol 1997;9:1329-1338.